WSTAM
LGND icon

Wilbanks Smith & Thomas Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-42
Closed -$7K – 886
2018
Q3 		$7K Buy
+42
New +$6.33K ﹤0.01% 1128

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's LGND Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Ligand Pharmaceuticals (LGND) in Q4 2018, closing a stake of 42 shares — an estimated $7K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in LGND in Q3 2018 and held it in 1 quarter. The position peaked at $7K in Q3 2018. 362 funds tracked by Wall St. Rank hold LGND as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Ligand Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 42 Ligand Pharmaceuticals shares in Q4 2018, an estimated $7K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Ligand Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's Ligand Pharmaceuticals position peaked at $7K in Q3 2018.
  • 362 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.